In Vivo CAR-M

About Carisma Therapeutics

Carisma Therapeutics is a pioneer in macrophage-based cell therapy, founded as a spin-out from the University of Pennsylvania. Its mission is to develop engineered CAR-Macrophage and CAR-Monocyte therapies to treat solid tumors and other serious diseases by harnessing cells that naturally infiltrate and remodel hostile tissue microenvironments. The company's strategy centers on advancing its lead anti-HER2 candidate, CT-0508, through Phase 1 trials while expanding its modular platform into new targets and indications, supported by experienced leadership and key academic collaborations. Carisma became a public company via a merger in March 2023.

Therapeutic Areas

Other Undisclosed Oncology Targets Drugs